Cannara Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cannara Biotech generated cash of $10,682,910, which is more than the previous year. Cash used in financing activities reached the amount of -$3,144,719 last year. Net change in cash is therefore $2,349,870.
Cash Flow
| 2018 | -1.15M | -14.99M | 29.04M |
|---|---|---|---|
| 2019 | -7.40M | -21.63M | 42.66M |
| 2020 | -9.32M | -8.55M | -914.81K |
| 2021 | -2.09M | -30.82M | 33.25M |
| 2022 | -6.07M | -15.34M | 25.46M |
| 2023 | 5.43M | -9.47M | -3.71M |
| 2024 | 10.68M | -5.18M | -3.14M |
LOVE.V Cash Flow Statement (2018 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.27M | 12.11M | 8.15M | 7.77M | 26.50M | 12.89M | 0 |
Operating activities | |||||||
Net income | 6.43M | 6.94M | 2.30M | -1.52M | -13.09M | -12.97M | -2.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 6.35M | 4.94M | 3.92M | 3.02M | 2.58M | 566.32K | 109.67K |
Stock-based compensation expense | 1.97M | 1.75M | 349.46K | 331.57K | 782.05K | 2.18M | 0 |
| Deferred income tax benefit | 1.97M | 1.75M | 349.46K | 331.57K | 782.05K | 2.18M | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -2.05M | -2.04M | -5.67M | -2.81M | 28.71K | 73.82K | -365.10K |
Inventories | -3.97M | -8.32M | -8.22M | -3.34M | -1.64M | -186.70K | 0 |
Accounts payable | 2.21M | 4.10M | 2.27M | 2.17M | 930.20K | 524.89K | 0 |
Cash generated by operating activities | 10.68M | 5.43M | -6.07M | -2.09M | -9.32M | -7.40M | -1.15M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -7.46M | -9.87M | -15.46M | -31.07M | -8.81M | -22.31M | -14.99M |
Acquisitions Net | 0 | 0 | 63.10K | 217.36K | 502.18K | 974.64K | 0 |
Cash generated by investing activities | -5.18M | -9.47M | -15.34M | -30.82M | -8.55M | -21.63M | -14.99M |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 24.75K | 24.3M | 696.79K | 46.23M | 17.66M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -277.13K | -374.48K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.03M | -2.24M | 27.57M | -668.27K | -6.56M | -235.45K | 0 |
Cash used in financing activities | -3.14M | -3.71M | 25.46M | 33.25M | -914.81K | 42.66M | 29.04M |
Net Change In Cash | 2.34M | -7.84M | 3.95M | 388.12K | -18.73M | 13.60M | 12.89M |
Cash at end of period | 6.62M | 4.27M | 12.11M | 8.15M | 7.77M | 26.50M | 12.89M |